MDxHealth SA Ordinary Shares
Here’s whether MDxHealth SA Ordinary Shares (MDXH) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-9.82% over 10 days); RSI 87 — overbought, elevated pullback risk; weak 1-year return of -71.5%; 3-month momentum negative (-9.5%); rising volume on a downtrend (distribution, 2.95x avg). Currently 84.8% off its 52-week high. Score: -5/7.
MDXH is trading below its 200-day MA ($2.37) — a key warning sign the longer-term trend is under pressure. With an RSI of 87.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -71.5% compares to +20.4% for SPY (trailed the market by 91.9%). The current 84.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.